+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Retinal Vein Occlusion Pipeline Analysis and Outlook, 2019

  • ID: 4772579
  • Report
  • May 2019
  • Region: Global
  • 87 pages
  • VPA Research
1 of 3


  • 3SBio Inc
  • Celon Pharma SA
  • Formycon AG
  • Kodiak Sciences Inc
  • Novartis Pharmaceuticals
  • Ohr Pharmaceutical Inc
  • MORE
Retinal Vein Occlusion pipeline

Retinal Vein Occlusion pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Retinal Vein Occlusion R and D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Retinal Vein Occlusion report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Retinal Vein Occlusion as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Retinal Vein Occlusion with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Retinal Vein Occlusion pipeline Profiled in detail

Key players actively participating in Retinal Vein Occlusion pipeline are profiled along with their R&D progress in Retinal Vein Occlusion treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Retinal Vein Occlusion pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Retinal Vein Occlusion treatment pipeline.

The report includes:
  • The research work provides comprehensive overview of Retinal Vein Occlusion pipeline and treatment landscape
  • Complete list of drug candidates from discovery to pre-registration phases are analyzed
  • Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio
  • Detailed drug profiles of Retinal Vein Occlusion pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed
  • Research and Development progress and trial details, results wherever available, are also included in the Retinal Vein Occlusion pipeline study
  • All recent news and developments related to Retinal Vein Occlusion drugs are provided
Note: Product cover images may vary from those shown
2 of 3


  • 3SBio Inc
  • Celon Pharma SA
  • Formycon AG
  • Kodiak Sciences Inc
  • Novartis Pharmaceuticals
  • Ohr Pharmaceutical Inc
  • MORE
1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Retinal Vein Occlusion Disease Overview

3. Retinal Vein Occlusion Research and Development Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Retinal Vein Occlusion Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Retinal Vein Occlusion Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Retinal Vein Occlusion companies
6.1.1 Business Profile
6.1.2. Pipeline Products
6.1.3. Retinal Vein Occlusion Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services
Note: Product cover images may vary from those shown
3 of 3


4 of 3
  • 3SBio Inc
  • Aerie Pharmaceuticals Inc
  • Aerpio Pharmaceuticals Inc
  • Annexin Pharmaceuticals AB
  • Celon Pharma SA
  • Chengdu Kanghong Pharmaceuticals Group Co Ltd
  • Clearside BioMedical Inc
  • EyeGate Pharmaceuticals Inc
  • Formycon AG
  • Gene Signal International SA
  • Graybug Vision Inc
  • Kodiak Sciences Inc
  • Mabion SA
  • Novartis Pharmaceuticals
  • Ocular Therapeutix Inc
  • Ohr Pharmaceutical Inc
  • Oxurion NV
  • Regeneron Pharmaceuticals Inc
  • Taiwan Liposome Company
Note: Product cover images may vary from those shown